Oncology & Cancer

Scientists find one-two punch for preclinical cancer models

A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models, according to a new publication ...

Oncology & Cancer

Increasing the effectiveness of immunotherapy against skin cancer

The melanoma is a malignant tumor of the pigment cells. If diagnosed early, the tumor can be removed completely—and the chances of recovery are good. But in later stages, when the tumor has already spread or formed metastases ...

Medications

PPI use is negative prognostic marker in urothelial cancer

(HealthDay)—For patients with advanced urothelial cancer treated with atezolizumab, proton pump inhibitor (PPI) use is a negative prognostic marker, according to a study published online Sept. 15 in Clinical Cancer Research.

Oncology & Cancer

Markers may predict patient response to immune therapy of cancer

For many individuals with different types of cancer, immune checkpoint inhibitors can effectively boost their immune system to fight their disease, but not all patients benefit from these medications. Now a team led by investigators ...

page 1 from 10